NCT03063164 is a NA clinical trial of Intralase IFS150 in Myopia, sponsored by Edward E. Manche.

Who is sponsoring NCT03063164?

NCT03063164 is sponsored by Edward E. Manche.

What drugs are being tested in NCT03063164?

Interventions in NCT03063164: Intralase IFS150, Visumax.

What condition does NCT03063164 study?

NCT03063164 studies Myopia, Astigmatism.

Is NCT03063164 still recruiting?

NCT03063164 is currently completed. Last updated 14 December 2021.

Are results published for NCT03063164?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-12-14 · How we verify

NCT03063164

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison of LASIK Outcomes Using Two Femtosecond Lasers

Completed NA Results posted Last updated 14 December 2021

What this trial tests

NA trial testing Intralase IFS150 in Myopia in 7 participants. Completed in 13 November 2018.

Timeline

14 February 2017

Primary endpoint
13 November 2018

13 November 2018

Quick facts

Lead sponsor	Edward E. Manche
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	14 February 2017
Primary completion	13 November 2018
Estimated completion	13 November 2018
Sites	1 location across United States

Drugs / interventions tested

Intralase IFS150
Visumax

Conditions studied

Myopia — all drugs for Myopia →
Astigmatism — all drugs for Astigmatism →

Sponsor

Edward E. Manche

Who can join

Adults 21 to 60, any sex, with Myopia or Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

ETDRS Uncorrected Visual Acuity Primary · At post-operative month 12

Number of eyes with an uncorrected visual acuity of 20/20 at 12 months measured using ETDRS testing charts

Group	Value	95% CI
Intralase IFS Eye	5
Visumax Eye	5

Cochet Bonnet Asthesiometry Measurement of Corneal Sensation Secondary · At postoperative month twelve

Cochet Bonnet Asthesiometry is measured on a scale of 1-6. Scores of 5 and above are considered normal.

Score of greater than or equal to 5

Group	Value	95% CI
Intralase IFS Eye	7
Visumax Eye	7

Score of less than 5

Group	Value	95% CI
Intralase IFS Eye	0
Visumax Eye	0

Best Spectacle Corrected Visual Acuity Secondary · Postoperative month 12

Number of eyes losing 2 or more lines of corrected distance visual acuity measured by ETDRS testing charts

Group	Value	95% CI
Intralase IFS Eye	0
Visumax Eye	0

Questionnaire Measuring Patient Preference for Laser Device Secondary · Intraoperative (Approximately 1 minute after completion of surgery)

Participants were asked if they preferred having LASIK surgery with either the Visumax laser, the Intralase iFS laser or had no preference between the two lasers.

Preferred Visumax

Group	Value	95% CI
All Participants	3

Preferred Intralase IFS

Group	Value	95% CI
All Participants	2

No preference

Group	Value	95% CI
All Participants	2

Sponsor's own description

Comparing LASIK outcomes using two femtosecond lasers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting
NCT07229365 — Children's Viewing Behavior · NA · recruiting

Other Edward E. Manche trials

Trials by the same sponsor.

NCT02161263 — Quality of Vision and Quality of Life With LASIK · completed
NCT01138189 — Wavefront-guided Versus Wavefront-optimized LASIK for Nearsightedness · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03063164 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Edward E. Manche
Last refreshed: 14 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03063164.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing